Dr.Shawon Hossen

Dr.Shawon Hossen A man is as big as his dream
MBBS
MRCP UK (London) Part-2
FCPS (Cardiology) Part-2 trainee

09/08/2025
29/03/2025
26/03/2025

đŸĢ€ āĻ­āĻŦāĻŋāĻˇā§āĻ¯ā§Ž āĻ•āĻžāĻ°ā§āĻĄāĻŋāĻ“āϞ⧋āϜāĻŋāϰ āĻāĻ•āϜāύ āĻĄāĻ•ā§āϟāϰ āĻšāĻŋāϏ⧇āĻŦ⧇,

āĻĻ⧇āĻļ⧇āϰ Cardiologist āϰāĻž āϝ⧇āĻ­āĻžāĻŦ⧇ āϤāĻžāĻŽāĻŋāĻŽ āχāĻ•āĻŦāĻžāϞ āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻŽā§ƒāĻ¤ā§āϝ⧂āϰ āĻšāĻžāϤ āĻĨ⧇āϕ⧇ āĻŦāĻžāϚāĻŋāĻā§Ÿā§‡ āφāύāϞ⧋ āϤāĻž āĻĻ⧇āϖ⧇ āύāĻŋāĻœā§‡āϕ⧇ āϏāĻ¤ā§āϝāĻŋ āϖ⧁āĻŦ āĻ—āĻ°ā§āĻŦāĻŋāϤ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇! âŖī¸

24/03/2025

āĻĻ⧇āĻļ⧇āϰ āĻ•ā§ŸāϟāĻŋ āĻœā§‡āϞāĻž āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āĻāϰāĻ•āĻŽ āĻŽā§āϝāĻžāϏāĻŋāĻ­ āĻ•āĻžāĻ°ā§āĻĄāĻŋ⧟āĻžāĻ• āĻāϰ⧇āĻ¸ā§āϟ āĻāϰ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏ⧁āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻž āφāϛ⧇?? āĻ•ā§ŸāϟāĻŋ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āĻāϤ⧋ āϤ⧜āĻŋā§Ž āĻ—āϤāĻŋāϤ⧇ āχāĻŽāĻžāĻ°ā§āĻœā§‡āĻ¨ā§āϏāĻŋ āϰ⧋āĻ—ā§€ āĻŽā§āϝāĻžāύ⧇āϜ āĻ•āϰāĻžāϰ āĻŦāĻ¨ā§āĻĻā§‹āĻŦāĻ¸ā§āϤ āφāϛ⧇? āĻĸāĻžāĻ•āĻžāϰ āĻŦāĻžāχāϰ⧇ āĻ•āĻŋ āχāĻŽāĻžāϰāĻœā§‡āĻ¨ā§āϏ⧀ āϰ⧋āĻ—ā§€ āύ⧇āχ? āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• āĻ…āĻ¨ā§āϝ āĻœā§‡āϞāĻžā§Ÿ āĻšā§ŸāύāĻž? āĻšāĻžāχ āĻĒā§āϰ⧋āĻĢāĻžāχāϞ āύāĻž āĻšāϞ⧇ āĻ•āĻŋ āĻ…āĻ¨ā§āϝāĻĻ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāĻžāĻŦāĻžāϰ āĻ…āϧāĻŋāĻ•āĻžāϰ āύ⧇āχ?

āĻāϤ⧋ āĻāϤ⧋ āĻĒā§āϰāĻļā§āύ āωāĻ¤ā§āϤāϰ āĻĻ⧇āĻŦāĻžāϰ āĻŽāϤ⧋ āϕ⧇āω āύ⧇āχāĨ¤āĨ¤āφāĻŽāĻžāĻĻ⧇āϰ āĻĻ⧇āĻļ⧇ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āĻ­āĻ™ā§āϗ⧁āϰ āĻ…āĻŦāĻšā§‡āϞāĻŋāϤ āĻāĻŦāĻ‚ āĻĻā§‚āĻ°ā§āύ⧀āϤāĻŋ āϤ⧇ āĻ­āϰāĻĒ⧁āϰ āĻāĻ•āϟāĻž āϜāĻžā§ŸāĻ—āĻž āĻšāϞ⧋ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āĻ–āĻžāϤāĨ¤āĨ¤āϝ⧇āĻ–āĻžāύ⧇ āĻļ⧁āϧ⧁ āϚāϞ⧇ āϏāĻŋāĻ¨ā§āĻĄāĻŋāϕ⧇āϟ āφāϰ āϟāĻžāĻ•āĻžāϰ āϖ⧇āϞāĻžāĨ¤āĨ¤ āĻāĻ•āϟāĻž āĻĻ⧇āĻļ⧇āϰ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āĻŦā§āϝāĻžāĻŦāĻ¸ā§āĻĨāĻž āϕ⧇āύ⧋ āĻ…āĻ¨ā§āϝ āĻĻ⧇āĻļ⧇āϰ āωāĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰāĻļā§€āϞ āĻšāĻŦ⧇ āϝ⧇āĻ–āĻžāύ⧇ āĻĸ⧇āϞ⧇ āϏāĻžāϜāĻžāύ⧋āϰ āϏ⧁āϝ⧋āĻ— āφāϛ⧇? āύāĻž āφāϛ⧇ āϕ⧋āύ⧋ āϰ⧇āĻĢāĻžāϰ⧇āϞ āϏāĻŋāĻ¸ā§āĻŸā§‡āĻŽ āύāĻž āφāϛ⧇ āϕ⧋āύ⧋ āχāĻŽāĻžāĻ°ā§āĻœā§‡āĻ¨ā§āϏāĻŋ āĻĒā§āϰāĻŸā§‹āĻ•āϞ āĻļ⧁āϧ⧁ āφāϛ⧇ āĻ­ā§‹āĻ—āĻžāĻ¨ā§āϤāĻŋ!!
āĻĒā§āϰāĻ¤ā§āϝ⧇āĻ• āϏāϰāĻ•āĻžāϰ āχ āφāϏ⧇ āύāϤ⧁āύ āύāϤ⧁āύ āĻ•ā§ŸāϟāĻž āĻŦāĻŋāĻ˛ā§āĻĄāĻŋāĻ‚ āĻŦāĻžāύāĻžā§Ÿ āύāĻžāĻŽ āĻĻā§‡ā§Ÿ āϏāϰāĻ•āĻžāϰāĻŋ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ..āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻ­āĻŋāϤāϰ⧇ āϝ⧇āύ āĻ āĻŋāĻ• āĻŽāĻžāĻ•āĻžāϞ āĻĢāϞ⧇āϰ āĻŽāϤ⧋āχāĨ¤āĨ¤
āĻāĻ•āϜāύ āĻšāĻžāĻ°ā§āϟ āĻ¸ā§āĻĒ⧇āĻļāĻžāϞāĻŋāĻˇā§āϟ āĻāϰ āĻĒā§‹āĻ¸ā§āϟāĻŋāĻ‚ āĻĨāĻžāϕ⧇ āωāĻĒāĻœā§‡āϞāĻžā§Ÿ āωāύāĻžāϰ āĻŦāϏ⧇ āĻŦāϏ⧇ āĻĒā§āϝāĻžāϰāĻžāϏāĻŋāϟāĻžāĻŽāϞ āφāϰ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ āĻŦāĻŋ āĻ•āĻŽā§āĻĒāϞ⧇āĻ•ā§āϏ āϞ⧇āĻ–āĻž āĻ›āĻžā§œāĻž āĻ•āĻžāϜ āύ⧇āχ..āϤāĻĻā§āϰ⧁āĻĒ āĻāĻŽāύ āĻ…āύ⧇āĻ• āĻ¸ā§āĻĒ⧇āĻļāĻžāϞāĻŋāĻˇā§āϟ āχ āφāϛ⧇āύ āϝāĻžāϰāĻž āĻ•āĻžāϜ āĻĒāĻžāϰ⧇āύ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϕ⧋āĻĨāĻžā§Ÿ āϤāĻžāϰ āĻĻāĻ•ā§āώāϤāĻž āĻĻ⧇āĻ–āĻžāĻŦ⧇āύ āϏ⧇āχ āϜāĻžā§ŸāĻ—āĻžāχ āĻĒāĻžāĻšā§āϛ⧇āύ āύāĻžāĨ¤āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻŦāĻŋāϕ⧇āĻ¨ā§āĻĻā§āϰ⧀āĻ•āϰāĻŖ āϝāϤāĻĻāĻŋāύ āύāĻž āĻšāĻŦ⧇..āϤāϤāĻĻāĻŋāύ āĻāχ āĻĻ⧇āĻļ⧇āϰ āĻŽāĻžāύ⧁āώ⧇āϰ āĻ­ā§‹āĻ—āĻžāĻ¨ā§āϤāĻŋ āĻ•āĻŽāĻŦ⧇ āύāĻžāĨ¤āĨ¤āĻĸāĻžāĻ•āĻž āĻ“ āĻ•āĻŋāϛ⧁ āĻŦāĻŋāĻ­āĻžāĻ—ā§€ā§Ÿ āĻœā§‡āϞāĻž āĻļāĻšāϰ⧇āϰ āĻŦāĻžāχāϰ⧇āϰ āϏāϰāĻ•āĻžāϰāĻŋ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ āϗ⧁āϞ⧋āϤ⧇ āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āχāϕ⧁āχāĻĒāĻŽā§‡āĻ¨ā§āϟ āϜāύāĻŦāϞ āχāĻŽāĻžāϰāĻœā§‡āĻ¨ā§āϏāĻŋ āĻŸā§āϰāĻžā§ŸāĻžāϜ āĻ•āĻŋāϛ⧁āχ āύ⧇āχ..āĻ•āύāϜāĻžāĻ°ā§āϭ⧇āϟāĻŋāĻ­ āĻŽā§āϝāĻžāύ⧇āϜāĻŽā§‡āĻ¨ā§āϟ āĻ›āĻžā§œāĻž āϏ⧇āĻ–āĻžāύ⧇ āφāĻĻ⧌āϤ⧇ āĻ•āĻŋāϛ⧁āχ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻŽāϤ⧋ āĻĨāĻžāϕ⧇āύāĻžāĨ¤āĨ¤ āĻĒ⧇āϰāĻŋāĻĢ⧇āϰ⧀āϰ āĻŽā§‡āĻĄāĻŋāϕ⧇āϞ āĻ•āϞ⧇āϜ āϗ⧁āϞ⧋āϤ⧇ āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āĻŸā§āϰ⧇āχāύāĻŋāĻ‚ āĻāĻŦāĻ‚ āĻŸā§āϰ⧇āχāύāĻžāϰ āĻāϰ āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻž āύāĻžāχ..āĻāχāϜāĻ¨ā§āϝ āĻĄāĻžāĻ•ā§āϤāĻžāϰ āϰāĻžāĻ“ āϏ⧇āĻ–āĻžāύ⧇ āĻĨāĻžāĻ•āϤ⧇ āϚāĻžāύ āύāĻž āĻĢāϞāĻžāĻĢāϞ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻ­ā§‹āĻ—āĻžāĻ¨ā§āϤāĻŋ āφāϰ āĻĻāĻžāϞāĻžāϞ āĻĻ⧇āϰ āĻĻ⧌āϰāĻžāĻ¤ā§āĻŽāĨ¤āĨ¤ āĻāĻ•āϟāĻž āĻĻ⧇āĻļ⧇ āϏāϰāĻ•āĻžāϰāĻŋ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ āϗ⧁āϞ⧋āϰ āĻšā§‡ā§Ÿā§‡ āĻ•āĻ°ā§āĻĒā§‹āϰ⧇āϟ āĻ•ā§āϞāĻŋāύāĻŋāĻ• āĻŦ⧇āĻļāĻŋ āϏāĻŽā§ƒāĻĻā§āϧ āĻāχāϜāĻ¨ā§āϝ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ⧇āϰ āĻŽāϤ āĻŽā§ŒāϞāĻŋāĻ• āĻ…āϧāĻŋāĻ•āĻžāϰ āĻĨ⧇āϕ⧇ āϖ⧇āĻŸā§‡ āĻ–āĻžāĻ“ā§ŸāĻž āĻ—āϰ⧀āĻŦ āĻŽāĻžāύ⧁āώ āϰāĻž āĻ…āύ⧇āĻ• āϟāĻžāχ āĻŦāĻžā§āϚāĻŋāϤāĨ¤āĨ¤

āĻāχ āĻĻ⧇āĻļ⧇ āϰāĻžāϜāύ⧈āϤāĻŋāĻ• āĻĒāϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ⧇āϰ āĻŦāĻŋāĻĒā§āϞāĻŦ āĻšāϤ⧇ āĻĒāĻžāϰ⧇..āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝāϰ āĻŽāϤ⧋ āĻāϤ⧋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϜāĻžā§ŸāĻ—āĻžā§Ÿ āϕ⧋āύ⧋ āĻŦāĻŋāĻĒā§āϞāĻŦ āĻšā§ŸāϤ⧋ āĻ•āĻ–āύ⧋āχ āĻšāĻŦ⧇āύāĻž..āφāĻŽāĻžāϰ āĻœā§€āĻŦāĻĻā§āĻĻāĻļāĻžā§Ÿ āĻšā§ŸāϤ⧋ āĻĻ⧇āĻ–āĻžāϰ āϏ⧁āϝ⧋āĻ— āĻšāĻŦ⧇āύāĻž..āĻ•āĻžāϰāĻŖ āĻšāĻžāχ āĻĒā§āϰ⧋āĻĢāĻžāχāϞ āύ⧀āϤāĻŋ āύāĻŋāĻ°ā§āϧāĻžāϰāĻ• āĻ“āχ āϝ⧇ āωāĻĻā§āϧ⧋āϧāύ⧇āϰ āĻĻāĻŋāύ āϞāĻžāϞ āĻ—āĻžāϞāĻŋāϚāĻžā§Ÿ āĻĢ⧁āϞ⧇āϰ āĻŦ⧁āϕ⧇āϟ āĻšāĻžāϤ⧇ āύāĻŋā§Ÿā§‡ āĻŦāĻŋāĻļā§āϰ⧀ āĻšāĻžāϏāĻŋ āĻĻāĻŋā§Ÿā§‡ āĻŽā§‹āύāĻžāϜāĻžāϤ āĻ•āϰ⧇ āφāϏ⧇āύ..āϤāĻžāϰāĻĒāϰ āφāϰ āϰ⧋āĻ—ā§€ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻ•āĻ–āύ⧋āχ āϤāĻžāĻĻ⧇āϰ āĻŦāĻž āϤāĻžāĻĻ⧇āϰ āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ•āĻžāωāϕ⧇ āϏ⧇āϏāĻŦ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āϝ⧇āϤ⧇ āĻšā§ŸāύāĻž!!

#āϰāĻŋāĻĢāĻ°ā§āĻŽāĻšā§‡āϞāĻĨāϏāĻŋāĻ¸ā§āĻŸā§‡āĻŽ āĻ…āĻĢ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ

#āĻ¸ā§āϟāĻĒāϏāĻŋāĻ¨ā§āĻĄāĻŋāϕ⧇āϟ

When everyone is waiting for Your failure, but you did it đŸ”Ĩ 😎
24/03/2025

When everyone is waiting for Your failure,
but you did it đŸ”Ĩ 😎

21/03/2025

🚩DIC

Disseminated intravascular coagulation (DIC) is a systemic disorder characterized by widespread activation of the coagulation cascade, leading to microvascular thrombosis and consumption of platelets and clotting factors, that results in both hemorrhagic and thrombotic manifestations..
Presents with bleeding from IV sites or catheter or body orifices.
🔰Etiologies:- Trauma, Sepsis, Tumor, APML, Obstetric complications and Acute pancreatitis.
🔰Pathophysiology:-
1. Tissue factor (released from endothelial cells) activates coagulation pathway (i.e. leads to thrombosis).
2. t-PA (released from endothelial cells) activates fibrinolytic pathway (i.e. leads to fibrinolysis); There is increase in plasma activator inhibitor-1 (PAI-1) which prevents the inhibition of fibrinolysis.
Diagnosis:-
1. CBC shows low platelet count (i.e. thrombocytopenia).
2. Coagulation profile shows elevated bleeding time, PT, aPTT, D-dimer and fibrin degradation products and low clotting factors and fibrinogen.
3. PBS shows schistocytes.
4. Deranged RFT and LFT.
đŸŸĸTreatment:-
1. Treat the underlying disease.
2. Platelet transfusions, FFP, cryoprecipitate if active bleeding.
3. Prophylactic anticoagulation with heparin or low molecular weight heparin (LMWH) should be given in patients who are not actively bleeding.
🔰Laboratory findings of DIC:- elevated PT, aPTT, and bleeding time; elevated D-dimer, fibrin degradation products; decreased platelets, clotting factors, and fibrinogen.
Happy learning âœŒī¸

14/03/2025

āϰ⧋āϜāĻž āϰ⧇āϖ⧇ āϰāĻ•ā§āϤ⧇āϰ āĻ—ā§āϞ⧁āϕ⧋āĻœā§‡āϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻĻ⧇āĻ–āϤ⧇ āϕ⧋āύ āĻŦāĻžāϧāĻž āύ⧇āχ

12/03/2025

&_Nails

Address

Dhaka
1217

Alerts

Be the first to know and let us send you an email when Dr.Shawon Hossen posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram